CAPTRUST Financial Advisors
CBIO icon

CAPTRUST Financial Advisors’s Crescent Biopharma CBIO Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2
Closed – – 4562
2021
Q1 		$0 Buy
+2
New +$716 ﹤0.01% 4400

Other funds holding CBIO

BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CAPTRUST Financial Advisors's CBIO Position: Q2 2021 in Review

CAPTRUST Financial Advisors sold out of Crescent Biopharma (CBIO) in Q2 2021, closing a stake of 2 shares.

CAPTRUST Financial Advisors first reported a position in CBIO in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 58 funds tracked by Wall St. Rank hold CBIO as of Q2 2021.

  • CAPTRUST Financial Advisors reported no remaining Crescent Biopharma position as of Q2 2021 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 2 Crescent Biopharma shares in Q2 2021.
  • CAPTRUST Financial Advisors first reported a position in Crescent Biopharma in Q1 2021 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Crescent Biopharma position peaked at $0 in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2021.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.